Ore Pharmaceutical drops SEC report filing

In an effort to cut costs, Ore Pharmaceutical Holdings Inc. has filed to terminate its common stock registration and free the Cambridge pharmaceuticals asset management company from obligations to file reports with the U.S. Securities and Exchange Commission.

Ore Pharmaceutical said in a press release today that its board of directors has approved the action and that the company expects to save money associated with the SEC reports by no longer accumulating legal, accounting and compliance costs.